FDA Signals Shift In Thinking On Biosimilar Trials
Agency Moves Towards Streamlined Filings With Advice To Xbrane And Formycon
Two recent disclosures from Xbrane Biopharma and Formycon demonstrate how the US Food and Drug Administration’s thinking is evolving on the necessity of Phase III trials to support biosimilar filings.
